Novavax (NVAX) announced Thursday it would have to push back its COVID-19 vaccine emergency use authorization (EAU) filing with the FDA by about one month, once again, this time due to manufacturing quality concerns. CEO Stanely Erck told Yahoo Finance Novavax itself did not delay the filing. Instead, he said, outside firms that the company was directed to work with by Operation Warp Speed — the former government program launched under the Trump administration to fund six vaccine candidates… Source link
Read More »Novavax CEO explains delay in COVID-19 vaccine EUA filing
